Blog - Page 1080 of 5757

MondayMar 28, 2022 12:27 pm

QualityStocksNewsBreaks – SPYR Inc. (SPYR) Announces Acquisition, Expansion Plans for 2022

SPYR (OTCQB: SPYR) (dba SPYR Technologies) is a technology company whose subsidiary, Applied Magix Inc., develops and resells Apple(R) ecosystem compatible products in the growing multibillion-dollar IoT smart home and connected car markets. The company today announced its acquisition and expansion plans for 2022. During fiscal year ended 2021 and to date, SPYR has been exploring possible acquisitions that may strengthen its balance sheet and return value to its shareholders. According to the update, SPYR has been in preliminary discussions with two companies targeted for possible acquisition this year. One of the targets is a well-positioned industrial lighting developer, whose…

MondayMar 28, 2022 12:04 pm

QualityStocksNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Announces Expected Report, Strengthened Balance Sheet

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, expects to report more than $65 million in cash and cash equivalents when it files Form 10Q for second quarter, the period ending March 31, 2022. The company has made significant progress and taken milestone steps during the quarter, including beginning trading on the Nasdaq Capital Markets LLC under the stock ticker symbol MULN. Mullen has also unveiled two versions of its Mullen FIVE show cars and purchased a vehicle manufacturing facility in Tunica, Mississippi. In addition, the company has entered into several key partnerships, with the expectation that these strategic…

MondayMar 28, 2022 11:42 am

QualityStocksNewsBreaks – Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) (FSE: 6BC0) Delayed in Filing Required Filings

Eat Well Group (CSE: EWG) (OTC: EGFF) (FSE: 6BC0) has announced an expected delay in filing its required filings for the year ended Nov. 30, 2021. Requested filings include the company’s audited annual financial statements, related management’s discussion and analysis, and certificates of its CEO and CFO. The company announced it will be delayed until after March 30, 2022, the filing deadline. The company has applied to the British Columbia Securities Commission (“BCSC”) for a management cease trade order (“MCTO”), while also noting that it is diligently working with its auditors to complete the required filings as soon as possible.…

MondayMar 28, 2022 9:15 am

Kronos Advanced Technologies Inc. (OTC: KNOS) Air Purifier Features Most Effective Technology Available

Air purifiers can improve indoor air quality, help soothe allergy and asthma symptoms, and rid air of toxins. Kronos’s proprietary, medical-grade technology has been tested as the most effective clean-air solution on the market. An air purifier “may be the household investment to make this year” (“USA Today”) The global pandemic has drawn attention to the fact that airborne particles can be dangerous, even life threatening. Kronos Advanced Technologies (OTC: KNOS) has developed one of the most effective air purifiers available today. One study attributed over two million deaths annually to indoor air pollution (https://ibn.fm/pwSst). Air purifiers are part of…

MondayMar 28, 2022 9:15 am

DGE’s 2nd Real World Evidence and Market Access Symposium to Access High Quality Data to Meet the Patient Needs

Life science executives are invited to attend the 2nd Real World Evidence and Market Access Symposium being held as a virtual event on April 11-12, 2022. The event is hosted by DGE, a leading global event management company that caters to the dynamic informational and networking needs of the pharmaceutical, biotechnology, health care, medical devices, and allied industries. The event centers around discussions, keynotes and sessions about the latest advances and best practices for harnessing real-world data insights that are productive for patients, payers and providers. Organizations can strengthen their business and reimbursement strategies by identifying and accessing the correct…

MondayMar 28, 2022 9:00 am

Delic Holdings Corp’s (CSE: DELC) (OTCQB: DELCF) Co-Founder and CEO Offers a Glimpse into the Company’s History and Future on The Jesse Tee Show

While appearing on The Jesse Tee Show, the company’s co-founder and CEO, Matt Stang, shared his professional background, Delic’s history, its growth, and its plans going forward Mr. Stang attributes its success to understanding where opportunities and people connect, how to make things win-win for all people, and giving customers value Founded in 2016, Delic Holdings Corp now has a market cap of $4.32 million as of March 2022 Delic Holdings (CSE: DELC) (OTCQB: DELCF) has been at the forefront of reframing the psychedelic conversation. It has also remained committed to bringing science-backed benefits of psychedelics to the health industry,…

MondayMar 28, 2022 9:00 am

Autonomous Security Robot Developer Knightscope Inc. (NASDAQ: KSCP) Explains IP Advantage as Nasdaq Listing Gains Attention

Artificial intelligence-enhanced security devices and big data collection are gaining popularity as means for strengthening companies’ footprints, particularly in response to criminal activity that can otherwise weaken operations Knightscope is a Silicon Valley-based company developing Autonomous Security Robots (“ASRs”) in response to America’s security needs, delivering a variety of models that observe and report on activity at client properties using powerful technological services Knightscope completed public listing on the Nasdaq Exchange in January 2022, enhancing awareness of its products and generating new inquiries about the nature of its services The company has taken note of its successes with its clients,…

MondayMar 28, 2022 9:00 am

Psychedelic Medicine Researcher Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Readies IND Application to Advance Drug Trials

Novel drug development company Mydecine Innovations Group is focusing on a medicinal pipeline for psychedelic drug candidates that have established some efficacy in treating mental illnesses — specifically addiction Mydecine is progressing in its clinical trial evaluation of its lead candidate, MYCO-001, and is finalizing an IND application with the FDA to begin patient dosing for its planned Phase 2 trials The company is targeting nicotine addiction in tobacco smokers Mydecine is also advancing its evaluation of other drug candidates with pending patents to enhance its existing products Medical-use psychedelic drug product developer Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF)…

FridayMar 25, 2022 3:50 pm

QualityStocksNewsBreaks – Nowigence Inc.’s Pluaris Enables Team Collaboration, Real-Time Sharing from Anywhere in the World

Nowigence has developed an off-the-shelf, cloud-based artificial intelligence (“AI”) platform called Pluaris(TM), designed specifically to help hobby readers, students and professionals (journalists, authors, researchers, and analysts) handle and organize the mass of material available. A recent article explains: “When the amount of material that readers want or need to process exceeds their capacity, several things can happen, including fatigue, inability to concentrate, or problems recalling information. It is precisely these problems that Pluaris is designed to solve. ‘Pluaris mimics the way that we, as humans, read, analyze and comprehend textual data,’ the company states.” Pluaris can analyze hundreds of pages…

FridayMar 25, 2022 3:40 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About Its Upcoming, Largest-Ever Hypertension Study

Lexaria Bioscience Corp. (NASDAQ: LEXX) remains committed to enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs. “Through its patented DehydraTECH(TM) drug delivery technology that began development in 2014, the company is offering potential solutions for conditions including, but not limited to hypertension, smoking cessation, anti-viral treatments, and other drug classes,” reads a recent article. The piece discusses significant developments Lexaria has made with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD. Given the success of previous studies, the company announced plans for more trials over 2022. “During 2021, we completed research &…

Site Search

Company Search

QualityStocksNewsBreaks – SPYR Inc. (SPYR) Announces Acquisition, Expansion Plans for 2022

QualityStocksNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Announces Expected Report, Strengthened Balance Sheet

QualityStocksNewsBreaks – Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) (FSE: 6BC0) Delayed in Filing Required Filings

Kronos Advanced Technologies Inc. (OTC: KNOS) Air Purifier Features Most Effective Technology Available

DGE’s 2nd Real World Evidence and Market Access Symposium to Access High Quality Data to Meet the Patient Needs

Delic Holdings Corp’s (CSE: DELC) (OTCQB: DELCF) Co-Founder and CEO Offers a Glimpse into the Company’s History and Future on The Jesse Tee Show

Autonomous Security Robot Developer Knightscope Inc. (NASDAQ: KSCP) Explains IP Advantage as Nasdaq Listing Gains Attention

Psychedelic Medicine Researcher Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Readies IND Application to Advance Drug Trials

QualityStocksNewsBreaks – Nowigence Inc.’s Pluaris Enables Team Collaboration, Real-Time Sharing from Anywhere in the World

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About Its Upcoming, Largest-Ever Hypertension Study

Market Basics

Newsletter Publishers

Public Companies